LMTM is being developed as a treatment targeting pathological aggregation of tau protein in AD and FTD [48,49,90,91], and this strategy appears promising since a correlation between the degree of tau aggregation and the severity of dementia has been established [12,13,37,45]. The gene discussed is MAPT; the disease is Alzheimer disease.